Colon dysplasia

Summary

Colon dysplasia (MONDO:0006151) is a disease and 9 clinical trials. Top therapeutic interventions include fluorescein and proflavine. A subtype of colonic disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 9

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	colon dysplasia
Mondo ID	MONDO:0006151
EFO	EFO:1000183
NCIT	C4847
SNOMED CT	308870004
UMLS	C1302363
MedGen	224903
Is cancer (heuristic)	no

Also known as: colonic dysplasia · dysplasia of colon · dysplasia of the colon

Disease family

This is a subtype of colonic disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › intestinal disorder › large intestine disorder › colonic disorder › colon dysplasia

Related subtypes (12): neuronal intestinal dysplasia, functional diarrhea, megacolon, diverticulitis of colon, cecal disorder, sigmoid disease, functional colonic disease, colitis, colonic neoplasm, polyp of colon, Chilaiditi syndrome, colonic duplication

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 9.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	7
PHASE4	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02688699	PHASE4	UNKNOWN	Additive Hemostatic Efficacy of EndoClot After EMR or ESD in the Gastrointestinal Tract
NCT01384240	EARLY_PHASE1	TERMINATED	Evaluation of a Low-Cost High Resolution Microendoscope for the Detection of Lower Gastrointestinal Neoplasia
NCT05463796	Not specified	RECRUITING	InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
NCT03139942	Not specified	COMPLETED	Optical Polyp Testing for In Vivo Classification
NCT03220711	Not specified	TERMINATED	Study of Performance of Confocal Endomicroscope With Fluorescein Imaging Agent in the Colon
NCT04191655	Not specified	COMPLETED	High Definition Colonoscopy (HDC) vs. Dye Spraying Chromo-colonoscopy (DSC) in Screening Patients With Long-standing Inflammatory Bowel Disease (IBD)
NCT05034185	Not specified	COMPLETED	Real-World Validation of an Artificial Intelligence Characterization Support (CADx) System
NCT05858970	Not specified	UNKNOWN	Diagnostic Accuracy of Real-time Optical Biopsy
NCT06223347	Not specified	UNKNOWN	Improved and Simplified Staining Technique for Dysplasia Detection in Colitis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
FLUORESCEIN	4	1
PROFLAVINE	2	4
CHEMBL177756	0	1